

| Research Ethics Committee Reference Number | Integrated Research Application System (IRAS) number | Submission Type | Name of Trial | Date of Receipt of Valid Research Application (old metric) | Date Site Invited (new metric) | Date Site Selected (new metric) | Date | Date Site Confirmed By Sponsor (new metric) | Date Site Confirmed (new metric) | Date Site Ready to Start (new metric) | | Non- Confirmation Status (new metric) | Duration between VRA / Date site selected and First Patient (days) | : Benchmark Met | A - Permissions delayed/ denied B - Suspended by sponsor | C - Closed by sponsor D - Sponsor Delays | E - Staff availability issues | F - No patients seen G - No patients | H - Contracting delays | J - Other | Comments | Reasons for delay correspond to: |
|--|---|--------------------|---|---|--------------------------------------|---------------------------------------|------------|--|--|---|------------|--|---|-----------------------|---|---|-------------------------------|---|------------------------|-----------|--|--|
| | | HRA Light | Hyperbaric oxygen treatment of mandibular osteoradionecrosis. A randomized clinical study. | | | | | | | | | | | | | | | | | | Sponsor delays with contract. Mandibular osteoradionecrosis is an unusual condition. The study requires low | |
| 12/NW/075: | :110644 | HRA Light | A RANDOMIZED, DOUBLE- BLIND, PLACEBO- CONTROLLED, MULTICENTER LONG-TERM SAFETY AND TOLERABILITY STUDY OF ETC 1002 IN PATIENTS WITH HYPERLIPIDEMIA AT HIGH CARDIOVASCULAR RISK WHO ARE NOT ADEQUATELY CONTROLLED BY THEIR LIPID- MODIFYING THERAPY | | 18/02/2016 | 5 24/08/2016 | 22/08/2016 | 19/10/2016 | 02/12/2016 | 18/01/2017 | 18/01/2017 | | 147 | No | | | | | Y | | participant numbers at site. | Sponsor |
| 16/LO/0553 | 194625 | | GALACTIC: GA-101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL | | 10/05/2016 | 5 05/07/2016 | 08/06/2016 | 22/06/2016 | 24/06/2016 | 19/07/2016 | 22/07/2016 | | 17 | Yes | | | | | | | Letter received from trial office 11/07/2016 advising that recruitment into GALACTIC is being stopped This is due to recruitment nationally being significantly slower than anticipated and trial office | |
| 14/YH/1199 | 153953 | HRA Light | Emergency Treatment with Levetiracetam or Phenytoin in Status Epilepticus in Children (EcLiPSE) – an open label randomised controlled trial | | 18/05/2016 | 6 06/07/2016 | 15/06/2016 | | | | | Sponsor declined site confirmation | | | | | | | | | no longer think it is achievable to meet the recruitment target. SIV 06/09/16. Sponsor delays with site initiation. Staff availability issues regarding the training of al staff in two department across two sites. Rare condition. | Sponsor |
| 15/NW/009 | 1162325 | HRA Light | A Trial for Older Patients with Acute Myeloid Leukaemia and High Risk | | 23/09/2015 | 14/07/2016 | 21/07/2016 | 10/08/2016 | 19/09/2016 | 31/10/2016 | 05/02/2017 | | 206 | No | | Υ | Y Y | | Y | | naic condition. | Both |
| 13/WA/020! | 127379 | HRA Light | Myelodysplastic Syndrome Adults with acute myeloid leukaemia or high-risk | | 05/09/2016 | 21/11/2016 | 15/06/2016 | 11/11/2016 | 21/11/2016 | 13/12/2016 | 06/01/2017 | | 46 | Yes | | | | | | | | |
| 14/WA/1056 | 154468 | HRA Light | | | | | | | | | | | | | | | | | | | | |



| Research Ethics Committee Reference Number | Integrated Research Application System (IRAS) number | Submission Type | Name of Trial | Date of Receipt of Valid Research Application (old metric) | Date Site Invited (new metric) | Date Site Selected (new metric) | HRA Approval Date (new metric) | Date Site Confirmed By Sponsor (new metric) | Date Site Confirmed (new metric) | Date Site Ready to Start (new metric) | Date of First Patient Recruited | Non- Confirmation Status (new metric) | Duration between VRA / Date site selected and First Patient (days) | Benchmark Met | A - Permissions delayed/ denied | sponsor | C - Closed by sponsor D - Sponsor Delays | E - Staff availability issues | F - No patients seen | G - No patients consented | H - Contracting delays | I - Rare diseases | J - Other | Comments | Reasons for delay correspond to: |
|--|---|--------------------|--|---|--------------------------------------|---------------------------------------|---|--|--|---|---------------------------------------|--|---|------------------|------------------------------------|---------|---|-------------------------------|----------------------|------------------------------|------------------------|-------------------|-----------|---|--|
| | | | OCTOPUS: Ovarian Cancer Trials of Weekly Paclitaxel - Umbrella StudyA Randomised, Phase II Umbrella Trial of a Weekly Paclitxel +/- Novel Agents in Platinum-Resistant Ovarian Cancer | | | | | | | | | | | | | | | | | | | | | | NHS |
| 15/LO/1302 | 169660 | HRA Light | | | 11/11/2016 | 09/01/2017 | 07/06/2016 | 03/05/2017 | 17/05/2017 | 07/06/2017 | | | | No | | | | Υ | | | | | | Internal capacity issues. | Provider |
| 15/EE/0421 | 101051 | | Pomalidomide in relapsed and refractory multiple myeloma | | 12/02/2017 | 30/03/2017 | 19/09/2016 | 24/04/2017 | 04/05/2017 | 08/06/2017 | | | | No | | | V | V | | | | | | Delays receiving study drug and lab kits at site. | Both |
| 15/EE/0421 | 191031 | | MILES - UK: Post Marketing, | | 13/03/2017 | 30/03/2017 | 16/06/2010 | 24/04/2017 | 04/05/2017 | 08/06/2017 | | | | Within | | | T | Ţ | | | | | | and iab kits at site. | DULII |
| BIO/MIL/01 | 135437 | HRA Light | Multicenter, Single Arm, Observational Clinical Registry to Evaluate Safety and Efficacy of BioMime Sirollimus Eluting Stent System In All Comers Real World Population With Coronary Artery Stenosis in United Kingdom. A randomised phase II trial | | 22/02/2017 | 10/05/2017 | 28/07/2016 | | | | | | | timeframe | | | | | | | | | | | |
| 15/NW/041 | 167060 | | A randomised phase II trial of Cyclophosphamide and Dexamethasone in combination with Ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenolidomide and bortezomib. | | 07/03/2017 | 06/04/2017 | | 19/05/2017 | 07/06/2017 | 28/06/2017 | | | | INO | | | | | | | Y | | | Delay due to additional contract with Myeloma UK caused by both NHS Provider and Myeloma UK. | NHS |